LivaNova (LIVN) announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services to seek reconsideration of national Medicare coverage for VNS Therapy in unipolar patients with treatment-resistant depression. The first step in the process for making a National Coverage Determination is the submission of a draft formal request for CMS reconsideration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- 3 Best Stocks to Buy Now, 5/23/2025, According to Top Analysts
- LivaNova Faces Legal Dispute Over Environmental Liabilities
- MongoDB and Asana downgraded: Wall Street’s top analyst calls
- Bullish Outlook for LivaNova: Growth in Cardiopulmonary and Epilepsy Segments with Promising Pipeline
- LivaNova upgraded to Outperform from Peer Perform at Wolfe Research